Thus, for the MEK inhibitor, BRAF mutation was associated with sensitivity when it occurred in the context of colon cancer and melanoma, while there were no association noted when it occurred in the context of other organ sites (Table S11 in File S3). Here, MAP2K7 is linked to melanoma.